Description
Pharmacological action of
Oxaliplatin is an antitumor drug belonging to a new class of platinum-based compounds in which the platinum atom forms a complex bond with 1,2-diaminocyclohexane (DACG) and the oxalate group.
Oxaliplatin has antitumor activity in various types of tumors, including colorectal cancer. It is also effective in the treatment of cisplatin-resistant tumors. The action is manifested regardless of the phase of the cell cycle. When used with fluorouracil, a synergism of the cytotoxic effect is observed. The mechanism of the antitumor effect of oxaliplatin is based on the cytotoxic effect and is not fully understood. Presumably, oxaliplatin forms inter- and intra-linkages with DNA, thereby inhibiting the phases of its replication and transcription.
Indications
Metastatic colorectal cancer in combination with fluoropyrimidines or, if possible, combination with ovarian cancer.
Contraindications
Hypersensitivity (including to other drugs containing platinum), pregnancy, lactation.
Special instructions
Use is possible only under the supervision of a physician with experience in chemotherapy. Prior to and during treatment (with small intervals), it is necessary to determine the level of blood cells, a complete neurological examination. In order to stop dyspeptic phenomena (nausea, vomiting), the appointment of antiemetics is necessary. In case of diarrhea, it is necessary to increase fluid intake. It is necessary to exclude contact with infectious patients or use non-specific measures for prevention (protective mask, etc.). During treatment, it is recommended to use adequate contraceptive measures. In case of contact of the drug with skin or mucous membranes, thorough washing with water is necessary. Dissolution, dilution and administration of the drug is carried out by trained medical personnel in compliance with protective measures (gloves, masks, clothing). When used in combination with fluoropyrimidines, it is introduced in front of them. Undiluted solutions should not be used. After the administration of oxaliplatin, the infusion system should be flushed before use to administer other drugs.
Composition of
1 ml – levofloxacin 5 mg, which corresponds to the content of levofloxacin hemihydrate sfldfdfdfdf1 5f1 565 mg 1 pflffdfdfdfdfdfdfdfdfdfdfdfdfdfdfdfdfdfdffdfdffdfdf1 vial) contains:
Active ingredients: oxaliplatin 5 mg (200 mg).
Excipients: lactose monohydrate, water d / and.
Dosage and administration
The drug is used only in adults. Injected intravenously in the form of 2-6-hour infusions. Hyperhydration with oxaliplatin is not required.
Side effects
Headache, dizziness, drowsiness, cramps, general weakness, peripheral sensory neuropathy, dysesthesia of the perioral region, upper respiratory tract and gastrointestinal tract, visual impairment, decreased appetite, nausea, vomiting, gastrointestinal bleeding, diarrhea, function myelodepression (leukopenia, granulocytopenia, thrombocytopenia, anemia), bleeding and hemorrhage hyperthermia, development of infections, rash, facial flushing, pneumosclerosis, lung infiltration, impaired sexual function and, teratogenicity, embryotoxicity, allergic reactions, including anaphylactoid.
Overdose
Symptoms: increased side effects. Treatment: symptomatic therapy, if necessary – transfusion of blood components, broad-spectrum antibiotic prescribing, monitoring of vital functions.
Storage conditions
In a dark place at a temperature of no higher than 15-25 ° C.
Expiration
2 years
Deystvuyuschee substances
oxaliplatin
Terms and conditions
Prescription
Dosage form
solution for infusion
Teva Pharmaceutical Enterprises Co., Ltd., Israel
